BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 21,810,000 shares, a growth of 22.0% from the June 30th total of 17,880,000 shares. Based on an average trading volume of 3,620,000 shares, the short-interest ratio is presently 6.0 days.

Insider Activity

In other news, Director Machelle Sanders sold 4,689 shares of the stock in a transaction on Monday, June 17th. The stock was sold at an average price of $6.00, for a total transaction of $28,134.00. Following the completion of the sale, the director now owns 27,742 shares in the company, valued at approximately $166,452. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Amy E. Mckee sold 8,600 shares of the stock in a transaction on Monday, June 24th. The stock was sold at an average price of $6.32, for a total transaction of $54,352.00. Following the completion of the sale, the director now owns 27,831 shares in the company, valued at approximately $175,891.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Machelle Sanders sold 4,689 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $6.00, for a total value of $28,134.00. Following the sale, the director now owns 27,742 shares of the company’s stock, valued at approximately $166,452. The disclosure for this sale can be found here. In the last 90 days, insiders purchased 103,601 shares of company stock worth $596,338. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Signaturefd LLC boosted its holdings in BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares in the last quarter. Panagora Asset Management Inc. boosted its holdings in BioCryst Pharmaceuticals by 2.8% in the second quarter. Panagora Asset Management Inc. now owns 650,318 shares of the biotechnology company’s stock worth $4,019,000 after purchasing an additional 17,759 shares in the last quarter. Leisure Capital Management bought a new stake in BioCryst Pharmaceuticals in the second quarter worth $173,000. Bank of New York Mellon Corp boosted its holdings in BioCryst Pharmaceuticals by 12.5% in the second quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company’s stock worth $4,795,000 after purchasing an additional 86,249 shares in the last quarter. Finally, Diversified Trust Co boosted its holdings in BioCryst Pharmaceuticals by 18.0% in the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 3,774 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research note on Tuesday, May 7th. Needham & Company LLC reissued a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

BioCryst Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ BCRX traded down $0.07 during mid-day trading on Tuesday, reaching $7.45. The company had a trading volume of 1,210,394 shares, compared to its average volume of 3,395,134. BioCryst Pharmaceuticals has a twelve month low of $4.03 and a twelve month high of $7.93. The stock’s 50 day moving average is $6.62 and its 200-day moving average is $5.74.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. The company’s revenue was up 34.9% compared to the same quarter last year. During the same period last year, the company posted ($0.28) earnings per share. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals will post -0.65 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.